Hemophilia Market in 7MM to Record 6.35% CAGR by 2023, States DelveInsight in Its In-demand Report Available at MarketPublishers.com15 May 2017 • by Natalie Aster
LONDON – Hemophilia is the most common type of inherited bleeding disorder in which a person lacks or has reduced levels of specific proteins termed ‘clotting factors’ and the blood does not clot in a proper way, which leads to excessive bleeding.
People with this condition experience continuous bleeding or oozing after an injury, surgical operation, or following tooth extraction. In severe cases, prolonged bleeding takes place after minor injury or even when there is not any injury (spontaneous bleeding). Severe complications can stem from bleeding into the joints, muscles, or other internals.
There are 3 forms of hemophilia, namely A, B, and C. Hemophilia A is the most typical form of the disease, which results from a deficiency in factor VIII. 8 out of 10 people with hemophilia have hemophilia A. Hemophilia B (otherwise termed Christmas disease) is caused by factor IX a deficiency. Hemophilia C is caused by a deficiency of factor XI, and is mild and rare form of hemophilia in which hemorrhaging usually occurs after an injury or surgery.
Across the 7MM, the size of the hemophilia market is projected to gather speed in the years to come, and it is projected to record a 6.35% CAGR by end-2023.
In-demand research publication “Hemophilia - Market Insights, Epidemiology and Market Forecast-2023” elaborated by DelveInsight is aimed at analysing the market on a global scale, with a specific focus on the USA, EU5 (France, Spain, Italy, Germany, and the UK) and Japan.
The report gives in-depth insights into disease etiology, path physiology, symptoms, disease diagnosis and management, as well as today’s treatment types. The research provides the market size of hemophilia globally and across 7 MM; covers total market share distribution of hemophilia for 7 MM from 2016 to 2023. The study contains marketed data comprising available prescribed medicines, patent and exclusivity information as well as drug sales to 2023. It sheds light on the trends shaping and driving the hemophilia marketplace, identifies the best opportunities for the 7 major markets for hemophilia. A review of the key market drivers and limiters is also at hand. The report cats light on the regulatory setting in the leading markets. It also contains historical and projected epidemiological data for the prevalent cases of the disease.
More in-demand reports by this publisher are available at the DelveInsight page.